TLR7 Agonist
Showing 1 - 25 of 4,264
Head and Neck Tumors Trial (TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 ß/?)
Not yet recruiting
- Head and Neck Neoplasms
- TransCon TLR7/8 Agonist
- +2 more
- (no location specified)
Aug 4, 2023
Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)
Completed
- Carcinoma, Hepatocellular
- +3 more
-
Duarte, California
- +9 more
Jan 27, 2023
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer Trial in New York (Radiation, Imiquimod, Cyclophosphamide)
Completed
- Breast Cancer
- +2 more
- Radiation
- +2 more
-
New York, New YorkNew York University Medical Center
Oct 25, 2021
HIV-1-infection Trial in Umlazi (Vesatolimod, VRC07523LS, CAP256V2LS)
Recruiting
- HIV-1-infection
- Vesatolimod
- +2 more
-
Umlazi, South AfricaFRESH Clinical Research Site: Females Rising through Education,
Jan 4, 2023
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Australia, United States (TransCon TLR7/8
Recruiting
- Advanced Solid Tumor
- +6 more
- TransCon TLR7/8 Agonist
- Pembrolizumab
-
Duarte, California
- +12 more
Sep 21, 2022
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Australia, United States (TransCon IL-2 ß/?,
Recruiting
- Advanced Solid Tumor
- +7 more
- TransCon IL-2 β/γ
- +4 more
-
Boston, Massachusetts
- +7 more
Nov 16, 2022
Solid Tumor Trial in Beijing (SHR2150, Anti-Cancer Agent)
Unknown status
- Solid Tumor
- SHR2150
- Anti-Cancer Agent
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Oct 15, 2020
Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)
Recruiting
- Myeloid Malignancies
- Lymphoid Malignancies
- NK Cell enriched-DLI only
- NK-DLI + DUK-CPG-001
-
Durham, North CarolinaDuke University Health System
Mar 8, 2022
HIV/AIDS Trial in Spain (ChAdOx1.HTI, MVA.HTI, GS-9620)
Active, not recruiting
- HIV/AIDS
- ChAdOx1.HTI
- +4 more
-
Badalona, Barcelona, Spain
- +8 more
Jul 30, 2021
Asthma Trial in Germany, United Kingdom (GSK2245035 Nasal Spray Solution, Placebo Nasal Spray Solution)
Completed
- Asthma
- GSK2245035 Nasal Spray Solution
- Placebo Nasal Spray Solution
-
Frankfurt, Hessen, Germany
- +5 more
Feb 26, 2021
Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Durvalumab
- Rintatolimod
-
Rotterdam, Zuid-Holland, NetherlandsErasmus MC
Jun 23, 2023
Melanoma Trial in Pittsburgh (drug, biological, other)
Recruiting
- Melanoma
- Vidutolimod (CMP-001)
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 25, 2022
Advanced Cancers, Melanoma Trial in Houston (MGN1703, Ipilimumab)
Active, not recruiting
- Advanced Cancers
- Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 11, 2022
HIV Trial in South Africa, United States (sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571)
Not yet recruiting
- HIV Infections
- sD-NP-GT8 DNA
- +4 more
-
Birmingham, Alabama
- +5 more
Mar 10, 2023
Locally Advanced Malignant Solid Tumor, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- +3 more
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
- VLP-encapsulated TLR9 Agonist CMP-001
-
Scottsdale, Arizona
- +3 more
Jun 1, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Anti-OX40 Antibody BMS 986178
- TLR9 Agonist SD-101
-
Palo Alto, CaliforniaStanford Cancer Institute Palo Alto
Jun 13, 2022
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,
Active, not recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-OX40 Antibody BMS 986178
- +3 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
May 3, 2022
Melanoma Trial in Houston (gp100, R848 gel, MAGE-3)
Completed
- Melanoma
- gp100
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jul 20, 2021
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Atlanta (VLP-encapsulated TLR9 Agonist CMP-001,,
Not yet recruiting
- Metastatic Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- VLP-encapsulated TLR9 Agonist CMP-001,
- Nivolumab
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 26, 2022
Solid Tumor Trial in Buffalo (entolimod, pharmacological study, laboratory biomarker analysis)
Completed
- Unspecified Adult Solid Tumor, Protocol Specific
- entolimod
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Melanoma, Lymph Node Cancer Trial in Pittsburgh (CMP-001, Nivolumab)
Active, not recruiting
- Melanoma
- Lymph Node Cancer
- CMP-001
- Nivolumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 15, 2022
HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)
Not yet recruiting
- HIV-1-infection
- ChAdOx1.tHIVconsv1
- +7 more
-
San Diego, California
- +11 more
Oct 4, 2023